IDEX Biometrics and Enqura to launch biometric smart cards in Turkey
OSLO, Norway, 10 November 2022 - IDEX Biometrics ASA and Enqura are collaborating to jointly develop and market biometric smart cards for digital authentication in Turkey. Enqura Information Technology is an ID verification solution provider with a strong client portfolio ranging from international and regional banks such as HSBC, Odeabank (Bank Audi), Burganbank, finance companies like ALJ Finance and investment companies like QNB Finans Invest. Additionally, Enqura’s partnership with Apple, Google and Microsoft puts them in an excellent position to go to market with the IDEX Biometrics smart card solutions in Turkey and across Europe.
Enqura facilitates the integration of the digital ID verification, and the collaboration with IDEX Biometrics in bringing to market biometric smart cards will accelerate the deployment of seamless and secure digital verification and authentication at global scale. These biometric smart cards are anticipated to reach the market in H1 2023.
“IDEX Biometrics continues to accelerate the commercial ecosystem development in Turkey and across Europe, capturing the increasing demand for secure digital authentication solutions. The collaboration between Enqura and IDEX Biometrics creates further opportunities for biometric smart cards” says Catharina Eklof, CCO of IDEX Biometrics. ”Enqura’s large portfolio of banks, fintechs and retailers will benefit from IDEX Biometrics industry leading technology and solutions for biometric smart cards, and as such speed up market launches at scale.”
“Enqura is delighted to bring more secure and convenient authentication solutions through this new strategic collaboration with IDEX Biometrics,” says Metin Karabiber, CEO of Enqura. “We see strong demand in the digital ID verification and authentication market. Adding biometrics to authenticate sign-in and for access enhances the user experience, removes the need for PINs and passwords, and mitigates the risk of fraud.”
For further information, contact:
Marianne Bøe, Head of Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel.: +47 918 00186
About IDEX Biometrics
IDEX Biometrics (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal authentication for all. We help people make payments, prove their identity, gain access to information or unlock devices with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast-growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com
About Enqura
Founded in 2014, Enqura provides enhanced technologies based on more than 15 years of information technology experience and highly skilled human capital. Enqura focuses on providing a “one stop shopping experience” for banks, insurtech and fintech companies through its AI and Blockchain based disruptive fintech products such as ID and Face verification, multi-factor customer authentication, mobile and web applications, digital wallets and corporate messaging/chat platform. Enqura is the leading ID verification and customer authentication company in Turkey.
For more information, visit www.enqura.com
TRADEMARK STATEMENT
IDEX, IDEX Biometrics and the IDEX logo are trademarks owned by IDEX Biometrics ASA. All other brands or product names are the property of their respective holders.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
23/2024・Trifork Group AG – Shareholders approve all resolutions at the Annual General Meeting 202419.4.2024 17:34:19 CEST | Press release
Company announcement no. 23 / 2024 Schindellegi, Switzerland – 19 April 2024 Shareholders approve all resolutions at the Annual General Meeting 2024 The shareholders of Trifork Group AG (“Trifork“) today approved all resolutions proposed by the Board of Directors at Trifork’s Annual General Meeting 2024 (the “AGM“) which was held at Grabenstrasse 2, 6430 Baar, Switzerland. Dividend payment The shareholders approved the Board of Directors’ proposal to pay a gross dividend of EUR 0.10 per share (equivalent to CHF 0.10 per share) by making a payout from capital contribution reserves to the shareholders. The total gross dividend paid out amounts to CHFk 1,932, equivalent to DKKk 14,809, as calculated per the exchange rate published by the Swiss Federal Customs Administration as of 19 April 2024. The payout from capital contribution reserves is declared in CHF and paid out in DKK. Composition of the Board of Directors The shareholders re-elected Julie Galbo as Chairperson of the Board of Di
Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding
Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release
Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release
Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and
Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 202419.4.2024 17:00:00 CEST | Press release
Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs (the “LTIP”) for Zealand's Board of Directors, Corporate Management and employees in accordance with Zealand's remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 2024 (“Remuneration Policy”). Long-term incentive program Zealand has made the following awards in its long-term incentive plan. It has awarded: 20,497 restricted stock units ("RSUs") to Zealand's Board of Directors 52,777 performance stock units ("PSUs") and 52,777 RSUs have been awarded to Zealand’s Corporat